Quality of Life in Acute Complicated and Chronic Recurrent Left-sided Diverticulitis
NCT ID: NCT05942833
Last Updated: 2025-09-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
136 participants
INTERVENTIONAL
2023-01-16
2027-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Quality Assessment in Endoscopic Retrograde Cholangiopancreatography(ERCP)
NCT02698137
Early (4 Days) Versus Standard Drainage of the Abdominal Cavity After Pancreaticoduodenectomy
NCT01368094
Laparoscopic Peritoneal Lavage vs Laparoscopic Sigmoidectomy in Perforated Acute Diverticulitis: a Multicenter Prospective Observational Study (STELLA Study)
NCT03008707
Hydrodissection of the Hepatoduodenal Ligament
NCT06190821
Laparoscopic Transvaginal Hybrid Anterior Resection: a Prospective Data Collection
NCT01043731
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Gastrointestinal Quality of Life Index (GIQLI)
Secondary endpoints:
SF-36 score (physical and mental health summary scores), LARS score, GIQLI-domains, anastomosis insufficiency and other complications, exitus and length of hospital stay
Treatment strategy:
A patient is coming into the hospital with acute symptoms of diverticulitis. The diagnosis must then be confirmed either with ultrasound or with a CT scan. After confirmation the patient is asked to be part of the study. At that point of time the patient does not know his randomization. After the patient's approval and signed consent the patients will bei informed about the further procedure and the appointment of surgery. Questionnaires will now be filled out and antibiotical treatment starts. If necessary a radiological intervention (drainage) is performed.
Is the patient is randomized into Group A he will get early left hemicolectomy immediately up to a maximum of 2 days after 7-10 days lasting initial conservative or interventional treatment (e.g: antibiotics, analgesics, drainage). If the patient is in Group B he will receive an elective left hemicolectomy 6 to 8 weeks after 7-10 days lasting initial conservative or interventional treatment (e.g: antibiotics, analgesics, drainage).
Reassessment of the questionnaires will bei done in both groups. Group A will be asked 6-8 after surgery and again 6-8 weeks after the second reassessment.
Group B will be asked 6-8 weeks after discharge (directly before surgery) and again 6-8 weeks after surgery.
The aim of the study is to evaluate the outcome and quality of life in patients receiving early surgery versus elective resection of the left-sided colon in acute complicated diverticulitis and chronic recurrent diverticulitis with acute exacerbation.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group A (Early)
Early left hemicolectomy immediately up to a maximum of 2 days after 7-10 days lasting initial conservative or interventional treatment (e.g: antibiotics, analgesics, drainage) and CT scan/ultrasound proven left-sided colonic diverticulitis
Sigmoid resection
Timing of sigmoid resection
Group B (Late)
Elective left hemicolectomy 6 to 8 weeks after 7-10 days lasting initial conservative or interventional treatment (e.g: antibiotics, analgesics, drainage) and CT scan/ultrasound proven left-sided colonic diverticulitis
Sigmoid resection
Timing of sigmoid resection
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Sigmoid resection
Timing of sigmoid resection
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* CDD Type 2a, 2b: acute complicated left-sided diverticulitis
* CDD Type 3b: relapsing diverticulitis without complications (\>2 episodes within 2 years)
* Acute presentation
* Inflammation located in the left-sided colon
* Inflammation is CT proven or ultrasound confirmed from experienced radiologists
Exclusion Criteria
* Pregnancy
* BMI \> 55kg/m2
* Current colorectal carcinoma in the left-sided colon
* Oral and/or intravenous corticosteroid
* Ongoing chemotherapy
* Status post left hemicolectomy
* Patients who cannot take care of themselves at home or are unable to follow instructions
* Patients who are not fit for surgery (anesthesia, expert knowledge from specialists) and will not benefit from surgery
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Krankenhaus Barmherzige Schwestern Linz
OTHER
Elisabethinen Hospital
OTHER
Universitätsmedizin Mannheim
OTHER
Kepler University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Andreas Shamiyeh, Dr.
Role: PRINCIPAL_INVESTIGATOR
Kepler University Hospital Linz
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ordensklinikum Elisabethinen Linz
Linz, Austria, Austria
Krankenhaus Barmherzige Schwestern Linz
Linz, Upper Austria, Austria
Kepler University Hospital
Linz, Upper Austria, Austria
Universitätsklinikum Mannheim
Mannheim, Mannheim, Germany
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Christoph Schwaiger-Hengstschläger, Dr.
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1203/2022
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.